Form 10-K405 - Annual report [Sections 13 and 15(d), S-K Item 405]:
SEC Accession No. 0001045969-99-000195
Filing Date
1999-03-30
Accepted
1999-03-30 00:00:00
Documents
10
Period of Report
1998-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K 10-K405 203354
2 TERMINATION AGREEMENT WITH JAMES V. ADAM EX-10.9 24552
3 TERMINATION AGREEMENT WITH LORI-JEAN GILLE EX-10.10 24414
4 TERMINATION AGREEMENT WITH CHARLES N. BLITZER EX-10.11 24415
5 EXCLUSIVE LICENSE AGREEMENT EX-10.25 96158
6 COMPUTATION OF NET LOSS PER SHARE EX-11 1141
7 INDEPENDENT AUDITORS CONSENT EX-23 935
8 POWER OF ATTORNEY EX-24 2274
9 FINANCIAL DATA SCHEDULE EX-27 2380
10 CAUTIONARY STATEMENTS EX-99 28308
  Complete submission text file 0001045969-99-000195.txt   410496
Mailing Address OPUS CENTER 9900 BREN ROAD EAST SUITE 300E MINNEAPOLIS MN 55343
Business Address 9900 BREN RD EAST STE 300E C/O OPUS CENTER MINNETONKA MINNESOTA MINNEAPOLIS MN 55343 6129357335
MGI PHARMA INC (Filer) CIK: 0000702131 (see all company filings)

EIN.: 411364647 | State of Incorp.: MN | Fiscal Year End: 1231
Type: 10-K405 | Act: 34 | File No.: 000-10736 | Film No.: 99578407
SIC: 2834 Pharmaceutical Preparations